GENE Jul 2024 2.500 call
| Previous close | 0.0500 |
| Open | 0.0500 |
| Bid | 0.0500 |
| Ask | 0.7500 |
| Strike | 2.50 |
| Expiry date | 2024-07-19 |
| Day's range | 0.0500 - 0.0500 |
| Contract range | N/A |
| Volume | |
| Open interest | 13 |
GlobeNewswireGeneType Identifies 79.5% of People Tested are at Risk of Serious Disease
Results from commercial sales of predictive testing across the US and Australia establish clear advantages of geneType Risk Assessment Tests for a more preventive approach in disease managementCHARLOTTE, N.C., June 25, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to share the power of the geneType test in identifying risk and improving the health of pop
- GlobeNewswire
Join Genetic Technologies’ Exclusive Live Investor Webinar and Q&A Session on June 27
CHARLOTTE, N.C. and MELBOURNE, Australia, June 21, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ:GENE, ASX:GTG, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on June 27, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Simon Morriss, CEO of Genetic Technologies, who will share insight into the Company’s
- GlobeNewswire
Genetic Technologies Expands Operational Capacity in North America
Global leader in personalized predictive genetics launches testing operations for geneType disease risk assessments at US based, world-leading genetic laboratory, Gene by GeneCHARLOTTE, N.C., June 18, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, today announces the start of testing operations in the United States for its revolutionary geneType™ genetic risk assess
